Press Release: Vybion : Vybion, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Market Research Report

(PR-inside.com) Vybion, Inc. (Vybion) is a development stage pharmaceutical company. It manufactures human monoclonal antibody drugs. The company's product pipeline portfolio spans indication, INT41, for polyglutamine diseases such as Huntington's, spinobublar muscular ataxia, spinocerebellar ataxia, and Alzheimer's. Vybion offers technologies namely, procode and pharmcode. It employs its proprietary ProCode technology for intrabody development for the treatment of neurodegenerative diseases. The company'S pharmcode technology uses dose and affinity of intrabodies to interrogate intracellular pathways. It works in partnership with Tulane Medical School, Corgenix, Scripps Institute, Harvard, and UCSD among others. The company has presence in Nigeria. Vybion is headquartered in Ithaca, New ..